A Phase 1, Two-part, Open-label, Single-oral-dose Study to Investigate the Absolute Bioavailability and Absorption, Pharmacokinetics, Distribution, Metabolism, and Excretion of [14C]-Derazantinib in Healthy Male Subjects
Latest Information Update: 26 Nov 2019
At a glance
- Drugs Derazantinib (Primary) ; Derazantinib (Primary)
- Indications Cholangiocarcinoma; Solid tumours; Urogenital cancer
- Focus Pharmacokinetics
- Sponsors Basilea Pharmaceutica
Most Recent Events
- 22 Nov 2019 Status changed from recruiting to completed.
- 26 Sep 2019 New trial record